This research presents formulation, development and evaluation of novel drug delivery system for treatment of Parkinson’s disease. Parkinson’s is neurodegenerative disease caused due to degeneration of dopaminergic neurons in substantia nigra. Tremors, rigidity, bradykinesia postural instability and poor walking result from deficiency of dopamine. There is a higher risk incidence in the elderly population. Levodopa improves motor symptoms but as the disease progresses, long-term use of levodopa often leads to complications like motor fluctuations and dyskinesia. Hence objective of the study is to construct a stable and easily administered nano- formulation with enhanced bioavailability by adding levodopa into nanocochleates. The developed formulation was optimized and evaluated for particle size, zeta potential, entrapment efficacy, PXRD, DSC, TEM, in-vitro drug release, kinetic study, pharmacological activities and stability studies. Cell line study is performed to evaluate protective effect of different formulations of levodopa on H2O2 induced cytotoxicity. Animal study of optimized formulation was performed on rat model of Parkinson’s disease induced by 6-hydroxy dopamine. The test performed on developed nanocochleates demonstrated controlled drug release kinetics, indicating improved drug bioavailability and an extended duration of therapeutic impact. Therefore, research showcased a nanocochleates-based nanocarrier system that possesses enhance drug delivery controlled release, increased stability, reduced dosage, and practical uses in the field of biomedicine.
Rawal et al. (Wed,) studied this question.